What is Remepy?
Remepy is at the forefront of developing Hybrid Drugs, a novel therapeutic approach that integrates software applications with traditional pharmaceutical components. The company's 'Digital Molecules' are designed to act as the software element within these hybrid treatments, enhancing brain functions that regulate neuro-endocrine and neuro-immunological systems, while also boosting neuroplasticity to optimize drug efficacy. By partnering with pharmaceutical companies, Remepy aims to bring these advanced treatments to market, offering tailored digital interventions and protocols that complement existing drug therapies for various medical conditions.
How much funding has Remepy raised?
Remepy has raised a total of $10M across 1 funding round:
Angel/Seed
$10M
Angel/Seed (2024): $10M with participation from Vine Ventures, Supernode Ventures, PsyMed Ventures, and The NFX
Key Investors in Remepy
Vine Ventures
Vine Ventures is a venture capital firm specializing in innovative health and wellness, particularly in life sciences and psychedelics, with a philanthropic commitment to mental health.
Supernode Ventures
Supernode Ventures, founded in 2017, invests in early-stage, sector-agnostic tech companies, with a focus on women's health and pre-seed/seed stage startups.
PsyMed Ventures
PsyMed Ventures is a venture capital fund dedicated to improving brain and mental health through investments in neurotechnology, digital health, and novel therapeutics.
What's next for Remepy?
With a recent major strategic investment, Remepy is poised to accelerate the development and market penetration of its innovative Hybrid Drugs. The company's focus on enhancing drug performance through digital interventions and personalized treatment protocols aligns with the growing trend towards precision medicine and digital therapeutics. Future endeavors will likely involve expanding strategic partnerships with pharmaceutical giants, further validating its Digital Molecules, and scaling its operations to meet the anticipated demand for these next-generation treatments. The substantial total funding indicates a strong investor confidence in Remepy's vision to revolutionize patient care through the fusion of digital technology and pharmaceuticals.
See full Remepy company page
